Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer.
RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine
alone as second line treatment for advanced non-small cell lung cancer.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine if Iscar improves immune function and quality of life.
Renato V. LaRocca, MD
Kentuckiana Cancer Institute
United States: Food and Drug Administration
|Kentuckiana Cancer Institute||Louisville, Kentucky 40202|